Suzetrigine

Class
Non-opioid analgesics
Subclass
Selective NaV1.8 sodium channel blockers
Substance name
Suzetrigine
Brand names
Journavx®
Common formulations
Film-coated tablet
Dosage and administration
Adults patients
Symptomatic relief of pain • Acute, moderate-to-severe
•
Loading: 100 mg PO once
•
Subsequently: 50 mg PO BID, starting after 12 hours of the initial dose, for up to 14 days
Take the first dose 1 hour before or 2 hours after food to prevent a delayed onset of action. Take subsequent doses with or without meals.
Indications for use
Labeled indications
Adults
•
Symptomatic relief of pain (acute, moderate-to-severe)
Safety risks
Contraindications
Concomitant use of strong CYP3A inhibitors
Warnings and precautions
Contraceptive failure
•
Use caution in patients taking concomitant hormonal contraceptives containing progestins other than levonorgestrel and norethindrone. Advise using additional nonhormonal contraceptive method or an alternative hormonal contraceptive during concomitant use and for 28 days after suzetrigine discontinuation.
Decreased drug efficacy
•
Use caution in patients taking sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy. Consider adjusting the concomitant CYP3A substrate dosage.
Increased plasma suzetrigine levels
•
Use caution in patients taking moderate CYP3A inhibitors. Reduce suzetrigine dosage.
Specific populations
Renal impairment
eGFR ≥ 15 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
eGFR < 15 mL/min/1.73 m²
•
Avoid use.
Renal replacement therapy
Any modality
•
No guidance available.
Hepatic impairment
Child-Pugh A (mild)
•
Use acceptable. No dose adjustment required.
Child-Pugh B (moderate)
•
Use with caution. Monitor for adverse reactions. Start at 100 mg PO for the first dose, then 50 mg PO BID for the second, third, and fourth doses. Reduce to 50 mg PO daily starting from the fifth dose.
Child-Pugh C (severe)
•
Avoid use.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Consider safer alternatives. Evidence of fetal harm in animals. Animal studies have shown effects on implantation, pregnancy maintenance, reduced mean gestation length, and increased postnatal fetal mortality, which are of uncertain relevance to humans.
Breastfeeding
Little information available on breastfeeding safety.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Common 1-10%
•
↑ serum CK, skin rash, muscle spasms, pruritus
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource